Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis

American Journal of Hypertension

Volumn 12, Issue 5, 1999, Pages 519-523

  Fukuhara, Masayo ^a,b   Matsumura, Kiyoshi ^a   Ohmori, Susumu ^a,b   Yanai, Toshiro ^a   Tsubota, Yoriaki ^a   Abe, Isao ^b   Fujishima, Masatoshi ^b  

^a KYUSHU CENTRAL HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Ambulatory blood pressure monitoring; Chronic hepatitis; Heart rate variability; Interferon; Sympathetic nervous system

Indexed keywords

INTERFERON;

ADRENERGIC SYSTEM; ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CHRONIC HEPATITIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HEART RATE VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; PULSE RATE; SYMPATHETIC TONE;

ANTIVIRAL AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY TEMPERATURE; CATECHOLAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0032965980     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00252-0     Document Type: Article

References (15)

1. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
2. Cohen M.C., Huberman M.S., Nest R.W. Recombinant alpha2 interferon-related cardiomyopathy. Am J Med. 85:1988;549-551.
3. Sonnenblick M., Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest. 99:1991;557-561.
4. Schechter D., Nagler A. Recombinant interleukin-2 and recombinant interferon α immunotherapy cardiovascular toxicity. Am Heart J. 123:1992;1736-1739.
5. Teragawa H., Hondo T., Amano H., et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 37:1996;905-915.
6. Katafuchi T., Hori T., Take S. Central administration of interferon-α enhances rat sympathetic nerve activity to the spleen. Neurosci Lett. 125:1991;37-40.
7. Blalock J.E., Smith E.M. Human leukocyte interferon (HuIFN-α) potent endorphin-like opioid activity . Biochem Biophys Res Commun. 101:1981;472-478.
8. Matsumura K., Abe I., Tominaga M., et al. Differential modulation by μ- and δ-opioids on baroreceptor reflex in conscious rabbits. Hypertension. 19:1992;648-652.
9. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation. 93:1996;1043-1065.
10. Tochikubo O., Ikeda A., Miyajima E., et al. Effects of insufficient sleep on blood pressure monitored by a new multibiomedical recorder. Hypertension. 27:1996;1318-1324.
11. Akaike H. Fitting autoregressive models for prediction. Ann Inst Stat Math. 21:1969;243-247.
12. Kirkwood J.M., Ernstoff M.S. Interferons in the treatment of human cancer. J Clin Oncol. 2:1984;336-352.
13. De Leeuw P.W., van Soest G.A.W., Punt R., et al. Neurohumoral response to hospitalization in hypertensive patients. Clin Sci. 61:1981;385s-387s.
14. Hossmann V., FitzGerald G.A., Dollery C.T. Influence of hospitalization and placebo therapy on blood pressure and sympathetic function in essential hypertension. Hypertension. 3:1981;113-118.
15. Mallani A., Pagani M., Lombardi F., et al. Spectral analysis to assess increased sympathetic tone in arterial hypertension. Hypertension. 17:(suppl III):1991;III-36-III-42.